Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The

Organic growth accelerated to 9% as acquired units and legacy markets recovered.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business reve

Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring other companies supplying the tools...

Apple's fiscal Q3 showed broad iPhone, Mac and Services demand, but rising costs, supply constraints and policy risks cloud the near-term outlook.

WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.

Moby summary of Waters Corporation's Q2 2026 earnings call

Waters Corp (WAT) delivered a 9% constant currency organic revenue beat in Q2 2026, prompting an upward revision to full-year guidance despite FX headwinds.

Waters Corporation (NYSE:WAT) reported second-quarter 2026 results that came in ahead of Wall Street expectations, supported by strong organic growth across its pharmaceutical and industrial businesses. The analytical instruments and diagnostics company’s shares were little changed in pre-market trading, edging up 0.

Waters (WAT) delivered earnings and revenue surprises of +1.33% and +1.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instruments company Waters Corporation (NYSE:WAT) announced better-than-expected revenue in Q2 CY2026, with sales up 113% year on year to $1.65 billion. The company expects next quarter’s revenue to be around $1.75 billion, close to analysts’ estimates. Its non-GAAP profit of $3.05 per share was 1.4% above analysts’ consensus estimates.

Scientific instruments company Waters Corporation (NYSE:WAT) will be reporting results this Tuesday before the bell. Here’s what to expect.

Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Waters (WAT) is back on investor radars after recent trading highlighted its role in analytical instruments and software used across pharmaceuticals, chemicals, and environmental testing. This has prompted a closer look at its valuation and fundamentals. See our latest analysis for Waters. At a share price of US$374.68, Waters has seen short term volatility, with the share price slipping 2.02% over the last day but gaining 24.98% over 90 days. The 1 year total shareholder return of 23.68%...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.

Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Waters Corporation (NYSE:WAT) and its peers.

Waters Corporation will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.